SCHEMBL10249219

SCHEMBL10249219

COc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)NCCCc2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.64
CCR9 P51686 1/20 0.57
NLRP3 Q96P20 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249477 0.94 KCNA5 (0.66) KCNA5CCR9NLRP3
SCHEMBL10249465 0.88 KCNA5 (0.82) KCNA5CCR9
SCHEMBL14267564 0.83 KCNA5 (0.70) KCNA5CCR9NLRP3
SCHEMBL23164974 0.82 RAB9A (0.72) KCNA5
SCHEMBL30527421 0.82 RAB9A (0.72) KCNA5
SCHEMBL10249599 0.81 GPR27 (0.66) KCNA5CCR9
SCHEMBL10249221 0.79 ACLY (0.67) CCR9
SCHEMBL27857 0.79 LMNA (0.77) CCR9
SCHEMBL10249564 0.78 LMNA (0.55) KCNA5CCR9
SCHEMBL5110940 0.77 SLC10A6 (0.68) CCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
US-20120014997-A1 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-01-19 US disclosed
US-20120014997-A1 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-01-19 US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 KCNA5 3907/4885CCR9 1/4885NLRP3 241/4885
US-20120014997-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 KCNA5 3907/4885CCR9 1/4885NLRP3 241/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 KCNA5 3907/4885CCR9 1/4885NLRP3 241/4885
US-20090163498-A1 Aryl Sulfonamides CCR9, CCR1, CCR2 KCNA5 3907/4885CCR9 1/4885NLRP3 241/4885
US-20130267492-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 KCNA5 3907/4885CCR9 1/4885NLRP3 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.